News-Papers
Testimonial
Video Gallery
Prostate cancer: GHRH antagonists could be effective in CRPC treatment
Published on Wednesday, 05 July 2017
About this comment from original article: Rick, F. G. et al. - Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of
ERK and Akt kinases. Proc. Natl Acad. Sci. USA 109, 1655–1660 (2012).
See also:
- Somatostatin in oncology, the overlooked evidences in the "Some additional publications about hGH/GH-GHRH/GHRF/GRF" section;
Search
Follow us...
Latest
- Prolactin inhibitors in oncology
- Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1
- A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin
- Adjuvant chemotherapy with melatonin for targeting human cancers: A review
- Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling
- Does the use of melatonin overcome drug resistance in cancer chemotherapy?
- Melatonin as a Promising Agent to Treat Ovarian Cancer: Molecular Mechanisms
- Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
- Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity
- Short Form 1b Human Prolactin Receptor Down-Regulates Expression of the Long Form
- Co-Administration of Curcumin and Bromocriptine Nano-liposomes for Induction of Apoptosis in Lung Cancer Cells
- Melatonin: an endogenous miraculous indolamine, fights against cancer progression
- Melatonin and breast cancer: Evidences from preclinical and human studies
- Melatonin induces autophagy in neuroblastoma by alleviating Pak2‑mediated endoplasmic reticulum stress
- In vivo dynamic monitoring of self-assembled melatonin nanodrug combined with photothermal effects to alleviate hypoxia to attenuate tumor aggressiveness
- Melatonin: An Endogenous Antiestrogen with Oncostatic Properties
- Modulating effects of famotidine and melatonin on high dose radiation induced cell lethality in normal human and cancer cell lines
- Plasma melatonin and the hormone-dependency of human breast cancer
Most Read
- The Di Bella Method (DBM)
- About melatonin - 1996
- All-trans-retinoic acid and cancer
- Biography
- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer
- Chronic Lymphocytic Leukemia: 4 patients, long-lasting remission
- Somatostatin in oncology, the overlooked evidences
- Bibliography
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report
- How effective is chemo therapy?
- Treatment of Low-grade Non-Hodgkin’s Lymphomas at Advanced Stage
- Complete objective response to biological therapy of plurifocal breast carcinoma
- Non-Hodgkin's Lymphoma, Stage III-B-E: a Case Report
- Vademecum
- Frequently Asked Questions
- Declaration recommends eliminate the use of Impact factor for research evaluation
- Non–Small-Cell Lung Cancer Patients with Low Performance Status: study on 28 patients
- Breast cancer: study on 122 cases. The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer